A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms

References

• Isaacs A, Lindenmann J. Virus interference I. The interferon. Proc. R. Soc. Lond. B. Biol. Sci.147, 258–267 (1957).
   PubMed Web of Science ®Google Scholar
• Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev.202, 8–32 (2004).
   PubMed Web of Science ®Google Scholar
• Krause CD, Pestka S. Evolution of the class 2 cytokines and receptors, and discovery of new friends and relatives. Pharmacol. Ther.106, 299–346 (2005).
   PubMed Web of Science ®Google Scholar
• Platanias LC. Mechanisms of type-I- and type-II-interferon mediated signalling. Nat. Rev. Immunol.5, 375–386 (2005).
   PubMed Web of Science ®Google Scholar
• de Weerd NA, Samarajiwa SA, Hertzog PJ. Type I interferon receptors: biochemistry and biological functions. J. Biol. Chem.282, 20053–20057 (2007).
   PubMed Web of Science ®Google Scholar
• Pestka S. The interferons: 50 years after their discovery, there is much more to learn. J. Biol. Chem.282, 20047–20051 (2007).
   PubMed Web of Science ®Google Scholar
• Tough DF, Sun S, Zhang X, Sprent J. Stimulation of naive and memory T cells by cytokines. Immunol. Rev.170, 39–47 (1999).
   PubMed Web of Science ®Google Scholar
• Ortaldo JR, Mason A, Rehberg E et al. Effects of recombinant and hybrid recombinant human leukocyte interferons on cytotoxic activity of natural killer cells. J. Biol. Chem.258, 15011–15015 (1983).
   PubMed Web of Science ®Google Scholar
• Cantell K, Hirvonen S, Kauppinen HL, Myllyla G. Production of interferon in human leukocytes from normal donors with the use of Sendai virus. Methods Enzymol.78(Part A), 29–38 (1981).
   PubMedGoogle Scholar
• Mellstedt H, Bjorkholm M, Johansson B, Ahre A, Holm G, Strander H. Interferon therapy in myelomatosis. Lancet313, 245–247 (1979).
   Google Scholar
• Kujawski LA, Talpaz M. The role of interferon-α in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev.18(5–6), 459–471 (2007).
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Cassinat B, Turlure P et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon α-2a. Blood108, 2037–2040 (2006).
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Chomienne C, Fenaux P. Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia22(11), 1990–1998 (2008).
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Cassinat B, Chevret S et al. Pegylated interferon-α-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood112, 3065–3072 (2008).
   PubMed Web of Science ®Google Scholar
• Larsen TS, Bjerrum OW, Pallisgaard N et al. Sustained major molecular response on interferon α-2b in two patients with polycythemia vera. Ann. Hematol.87, 847–850 (2008).
   PubMed Web of Science ®Google Scholar
• Larsen TS, Møller MB, de Stricker K et al. Minimal residual disease and normalization of the bone marrow after long-term treatment with α-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete haematological remission. Hematology14(6), 331–334 (2009).
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment? Leuk. Res.33(1), 11–18 (2009).
   PubMed Web of Science ®Google Scholar
• Silver RT, Vandris K. Recombinant interferon α (rIFN α-2b) may retard progression of early myelofibrosis. Leukemia23, 1366–1369 (2009).
   PubMed Web of Science ®Google Scholar
• Ianotto JC, Kiladjian JJ, Demory JL et al. PEG-IFN-α-2a therapy in patients with myelofibrosis: a study of the French Groupe d’Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myéloprolifératifs (FIM). Br. J. Haematol.146, 223–225 (2009).
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian HM, Manshouri T et al. Pegylated interferon-α-2a therapy yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J. Clin. Oncol.27, 5418–5424 (2009).
   PubMed Web of Science ®Google Scholar
• Bracada S, Eggermont AMM, Samuelsson J. Redefining the role of interferon in the treatment of malignant diseases. Eur. J. Cancer46, 284–297 (2010).
   PubMedGoogle Scholar
• Murphy PT, McPherson S, Langabeer SE. Complete molecular remission in a polycythaemia vera patient 12 years after discontinuation of interferon-α. Ann. Hematol.90(2), 233–234 (2011).
   PubMedGoogle Scholar
• Hasselbalch HC. Interferon α2 in the treatment of hematological malignancies. status and perspectives. Curr. Drug Targets12(3), 387–391 (2011).
   PubMedGoogle Scholar
• Hasselbalch HC, Larsen TS, Riley CH, Jensen MK, Kiladjian JJ. Interferon α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. status and perspectives. Curr. Drug Targets12, 392–419 (2011).
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC, Kiladjian JJ, Silver RT. Interferon alfa in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. J. Clin. Oncol.29, e564–e565 (2011).
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood117(18), 706–715 (2011).
   Google Scholar
• Silver RT, Vandris K, Goldman JJ. Recombinant interferon α may retard progression of early primary myelofibrosis: a preliminary report. Blood117(24), 6669–6672 (2011).
   PubMed Web of Science ®Google Scholar
• Preudhomme C, Guilhot J, Nicolini FE et al. SPIRIT Investigators; France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC). Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N. Engl. J. Med.363(26), 2511–2521 (2010).
   PubMed Web of Science ®Google Scholar
• Simonsson B, Hjorth-Hansen H, Bjerrum OW, Porkka K. Interferon α for treatment of chronic myeloid leukemia. Curr. Drug Targets12(3), 420–428 (2011).
   PubMed Web of Science ®Google Scholar
• Bjerrum OW. Interferon-α treatment in systemic mastocytosis. Curr. Drug Targets12(3), 433–436 (2011).
   PubMedGoogle Scholar
• Bjerrum OW. Interferon treatment in patients with hypereosinophilia. Curr. Drug Targets12(3), 429–432 (2011).
   PubMedGoogle Scholar
• Berneman ZN, Anguille S, Van Marck V, Schroyens WA, Van Tendeloo VF. Induction of complete remission of acute myeloid leukaemia by pegylated interferon-α-2a in a patient with transformed primary myelofibrosis. Br. J. Haematol.149(1), 152–155 (2010).
   PubMed Web of Science ®Google Scholar
• Anguille S, Lion E, Willemen Y, Van Tendeloo VF, Berneman ZN, Smits EL. Interferon-α in acute myeloid leukemia: an old drug revisited. Leukemia5, 739–748 (2011).
   Google Scholar
• Kimby E, Jurlander J, Geisler C et al. Nordic Lymphoma Group Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon α-2a: a randomized Phase II study from the Nordic Lymphoma Group. Leuk. Lymphoma49(1), 102–112 (2008).
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Sacchi S. Interferon: does it still have a role in the 21st Century? Leuk. Lymphoma50(10), 1562–1563 (2009).
   PubMedGoogle Scholar
• Baldo P, Rupolo M, Compagnoni A et al. Interferon-α for maintenance of follicular lymphoma. Cochrane Database Syst. Rev.1, CD004629 (2010).
   Google Scholar
• Khoo TL, Vangsted AJ, Joshua D, Gibson J. Interferon-α in the treatment of multiple myeloma. Curr. Drug Targets12(3), 437–446 (2011).
   PubMed Web of Science ®Google Scholar
• Carlo Stella C, Cazzola M. Interferons as biologic modulators of hematopoietic cell proliferation and differentiation. Haematologica73(3), 225–237 (1988).
   PubMedGoogle Scholar
• Gugliotta L, Bagnara GP, Catani L, Gaggiol L, Guarni A, Zauli G. In vivo and in vitro inhibitory effect of interferon on megakaryocyte colony growth in essential thrombocythemia. Br. J. Haematol.71, 177–181 (1989).
   PubMed Web of Science ®Google Scholar
• Chott A, Gisslinger H, Thiele J et al. Interferon-α-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis. Br. J. Haematol.74, 10–16 (1990).
   PubMed Web of Science ®Google Scholar
• Wadenvik H, Kutti J, Ridelli B et al. The effect of α-interferon on bone marrow megakaryocytes and platelet production rate in essential thrombocythemia. Blood77, 2103–2108 (1991).
   PubMed Web of Science ®Google Scholar
• Muller CA, Walz J, Zinser R, Buhring HJ, Steinke B, Schmidt H. In vivo induction of HLA molecules in patients with myeloproliferative syndrome during IFN-α treatment. Ann. Hematol.63, 259–263 (1991).
   PubMed Web of Science ®Google Scholar
• Borden EC, Wadler S. Interferons as biochemical modulators. J. Clin. Oncol.14(10), 2627–2630 (1996).
   PubMed Web of Science ®Google Scholar
• Grander D, Sangfelt O, Erickson S. How does interferon exert its cell growth inhibitory effect? Eur. J. Hematol.59, 129–135 (1997).
   PubMedGoogle Scholar
• Wang O, Miyakawa Y, Fox N et al. Interferon-α directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood96, 2093–2107 (2000).
   PubMed Web of Science ®Google Scholar
• Biron CA. Interferons α and β as immune regulators – a new look. Immunity14(6), 661–664 (2001).
   PubMed Web of Science ®Google Scholar
• Brassard DL, Grace MJ, Bordens RW. Interferon-α as an immunotherapeutic protein. J. Leucocyte Biol.71, 565–581 (2002).
   PubMed Web of Science ®Google Scholar
• Borden EC. Review: Milstein Award lecture: interferons and cancer: where from here? J. Interferon Cytokine Res.25(9), 511–527 (2005).
   PubMedGoogle Scholar
• Borden EC, Sen GC, Uze G et al. Interferons at age 50: past, current and future impact on biomedicine. Nat. Rev. Drug Discov.6(12), 975–990 (2007).
   PubMed Web of Science ®Google Scholar
• Rizza P, Moretti F, Belardelli F. Recent advances on the immunomodulatory effects of IFN-α: implications for cancer immunotherapy and autoimmunity. Autoimmunity43(3), 204–209 (2010).
   PubMed Web of Science ®Google Scholar
• Riley CH, Jensen MK, Brimnes MK et al. Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with interferon-α. Blood118(8), 2170–2173 (2011).
   PubMed Web of Science ®Google Scholar
• Gamero AM, Young HA, Wiltrout RH. Inactivation of Stat3 in tumor cells: releasing a brake on immune responses against cancer? Cancer Cell5, 111–112 (2004).
   PubMed Web of Science ®Google Scholar
• Wang T, Niu G, Kortylewski M et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med.10, 48–54 (2004).
   PubMed Web of Science ®Google Scholar
• Lesinski GB, Anghelina M, Zimmerer J et al. The antitumor effects of IFN-α are abrogated in A STAT1-deficient mouse. J. Clin. Invest.112, 170–180 (2003).
   PubMed Web of Science ®Google Scholar
• Yu H, Jove R. The STATs of cancer. New molecular targets come of age. Nat. Rev.4, 97–105 (2004).
   Google Scholar
• Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene19, 2468–2473 (2000).
   PubMed Web of Science ®Google Scholar
• Burdelya L, Kujawski M, Niu G et al. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide mediated antitumor effects. J. Immunol.174, 3925–3931 (2005).
   PubMed Web of Science ®Google Scholar
• Yang J, Chatterjee-Kishore M, Staugaitis SM et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res.65, 939–947 (2005).
   PubMed Web of Science ®Google Scholar
• Skov V, Larsen TS, Thomassen M et al. Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis. Eur. J. Haematol.87(1), 54–60 (2011).
   PubMed Web of Science ®Google Scholar
• Peschel C, Aulitzky WE, Huber C. Influence of interferon-α on cytokine expression by bone marrow microenvironment – impact on treatment of myeloproliferative disorders. Leuk. Lymph.22(Suppl. 1), 129–134 (1996).
   PubMed Web of Science ®Google Scholar
• Sacchi S, Leono P, Liberati M et al. A prospective comparison between treatment with phlebotomy alone and interferon-α in patients with polycythemia vera. Ann. Hematol.68, 247–250 (1994).
   PubMed Web of Science ®Google Scholar
• Brand CM, Leadhester L, Budiman R, Lechner K, Gisslinger H. Succesful re-treatment of an anti-interferon resistant polycythemia vera patient with lymphoblastoid interferon-αN1 and in vitro studies on the specificity of the antibodies. Br. J. Haematol.86, 216–218 (1994).
   PubMed Web of Science ®Google Scholar
• Merup M, Tornebohm-Roche E, Engman K, Paul C. Human leucocyte interferon-α therapy can induce a second response in treatment of thrombocytosis in patients with neutralising antibodies to recombinant interferon-α2a. Eur. J. Cancer30A, 1729–1730 (1994).
   PubMed Web of Science ®Google Scholar
• Tornebohm-Roche E, Merup M, Lockner D, Paul C. α-2a interferon therapy and antibody formation in patients with essential thrombocythemia and polycythemia vera with thrombocytosis. Am. J. Hematol.48, 163–167 (1994).
   Web of Science ®Google Scholar
• Stasi R, Brunetti M, Bussa S et al. Efficacy and safety of human leucocyte interferon-α treatment in patients younger than 60 years of age with polycythemia vera. J. Intern. Med.242, 143–147 (1997).
   PubMedGoogle Scholar
• Stasi R, Venditti A, Del Poeta G et al. Role of human leucocyte interferon (α) in the treatment of patients with polycythemia vera. Am. J. Med. Sci.315, 237–241 (1998).
   PubMedGoogle Scholar
• Merup M, Aberg W, Lowenberg E et al. Symptoms, symptom distress and health related quality of life in patients with polycythemia vera or essential thrombocythemia during treatment with interferon-α. Acta Oncol.41, 50–55 (2002).
   PubMed Web of Science ®Google Scholar
• Yanai Y, Sanou O. Analysis of the antiviral activities of natural IFN-α preparations and their subtype compositions. J. Interferon Cytokine Res.21, 835–841 (2001).
   PubMedGoogle Scholar
• Hibbert L, Foster GR. Human type I interferons differ greatly in their effects on the proliferation of primary B cells. J. Interferon Cytokine Res.19, 309–318 (1999).
   PubMedGoogle Scholar
• Ortaldo JR, Herberman RB. A species of human α interferon that lacks the ability to boost human natural killer activity. Proc. Natl Acad. Sci. USA81, 4926–4929 (1984).
   PubMed Web of Science ®Google Scholar
• Greiner JW, Fischer PB. Differential effects of recombinant human leucocyte interferons on cell surface antigen expression. Cancer Res.46, 4984–4990 (1986).
   PubMedGoogle Scholar
• Hilkens CMU, Schhlaak JF. Differential responses to IFN-α subtypes in human T cells and dendritic cells. J. Immunol.171, 5255–5263 (2003).
   PubMed Web of Science ®Google Scholar
• Kawade Y, Watanabe Y. Neutralization of interferon by antibody: appraisals of methods of determining and expressing the neutralizing titre. J. Interferon Res.4, 571–584 (1984).
   PubMedGoogle Scholar
• Steis RG, Smith JW, Urba WJ et al. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N. Engl. J. Med.318, 1409 (1988).
   PubMed Web of Science ®Google Scholar
• Catani L, Gugliotta L, Zauli G et al.In vitro inhibition of interferon α-2a antiproliferative activity by antibodies developed during treatment for essential thrombocythemia. Hematologica77, 318–321 (1989).
   Google Scholar
• von Bussow P, Jakschies D, Freund M et al. Treatment of antirecombinant interferon-α 2 antibody positive patients with natural interferon-α. Br. J. Haematol.78, 210–216 (1991).
   PubMedGoogle Scholar
• Antonelli G, Currenti M, Turriziani O, Dianzani F. Neutralising antibodies to interferon-α: relative frequency in patients treated with different interferon preparations. J. Infect. Dis.163, 882–885 (1991).
   PubMedGoogle Scholar
• Singal AK, Jampana SC, Anand BS. Peginterferon α-2a is superior to peginterferon α-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials. Dig. Dis. Sci.56(8), 2221–2226 (2011).
   PubMed Web of Science ®Google Scholar
• Linkesch W, Gisslinger H, Ludwig H, Flener R, Sinzinger H. Therapy with interferon (recombinant IFN-α-2C) in myeloproliferative diseases with severe thrombocytosis. Acta Med. Austriaca12, 123–127 (1985).
   PubMedGoogle Scholar
• Lengfelder E, Griesshammer M, Hehlmann R. Interferon-α in the treatment of essential thrombocythemia. Leuk. Lymphoma22(Suppl. 1), 135–142 (1996).
   PubMed Web of Science ®Google Scholar
• Barbui T, Barosi G, Birgegard G et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J. Clin. Oncol.29(6), 761–770 (2011).
   PubMed Web of Science ®Google Scholar
• Middelhoff G, Boll I. A long-term clinical trial of interferon α therapy in essential thrombocythemia. Ann. Hematol.64, 207–209 (1992).
   PubMed Web of Science ®Google Scholar
• Kasparau H, Bernhard M, Krieger O, Lutz D. Remission may continue after termination of rIFN α-2b treatment for essential thrombocythemia. Eur. J. Hematol.48, 33–36 (1992).
   PubMed Web of Science ®Google Scholar
• Sacchi S, Tabilio A, Leoni P et al. Sustained complete hematological remission in essential thrombocythemia after discontinuation of long-term αIFN treatment. Ann. Hematol.66, 245–246 (1993).
   PubMed Web of Science ®Google Scholar
• Giles F. Maintenance therapy in myeloproliferative disorders: the current options. Br. J. Haematol.79(Suppl. 1), 92–95 (1991).
   PubMed Web of Science ®Google Scholar
• Lopes E, Ribeiro MM, Silva MJ, Gandra M, Principe F, Granato C. Essential thrombocythemia: clinical features, therapy and follow up of 12 cases. Leukemia6(Suppl. 3), 138S–140S (1992).
   PubMedGoogle Scholar
• Gisslinger H, Chott A, Scheithauer W, Gilly B, Linkesch W, Ludwig H. Interferon in essential thrombocythemia. Br. J. Haematol.79(Suppl. 1), 42–47 (1991).
   PubMed Web of Science ®Google Scholar
• Alvarado Y, Cortes I, Verstovsek S et al. Pilot study of pegylated interferon α 2b in patients with essential thrombocythemia. Cancer Chemother. Pharmacol.51, 81–86 (2003).
   PubMed Web of Science ®Google Scholar
• Langer C, Lengfelder E, Thiele J et al. Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a Phase II study. Haematologica90, 1333–1338 (2005).
   PubMedGoogle Scholar
• Gugliotta L, Bulgarelli S, Vianelli N et al. PEG intron treatment in 90 patients with essential thrombocythemia (ET). Final report of a Phase II study. Blood (ASH Annual Meeting Abstracts)106, abstract 2600 (2005).
   Google Scholar
• Quintas-Cardama A, Kantarjian HM, Giles F, Verstovsek S. Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders. Semin. Thromb. Hemostas.32, 409–414 (2006).
   PubMed Web of Science ®Google Scholar
• Samuelsson J, Hasselbalch H, Bruserod O et al. A Phase II trial of pegylated interferon α-2b therapy for polycythemia vera and essential thrombocythemia. Feasibility, clinical and biologic effects, and impact on quality of life. Cancer106, 2397–2405 (2006).
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, Cortes J et al. PEG-IFN-α-2b therapy in BCR-ABL-negative myeloproliferative disorders. Final results of a Phase 2 study. Cancer110, 2012–2016 (2007).
   PubMed Web of Science ®Google Scholar
• Berte R, Vallisa D, Ferrai B, Civardi G, Sbolli G, Cavanna L. Low dose interferon α treatment in essential thrombocythemia. Eur. J. Haematol.56, 104–105 (1996).
   PubMed Web of Science ®Google Scholar
• Kozlowski A, Charles SA, Harris JM. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs15, 419–429 (2001).
   PubMed Web of Science ®Google Scholar
• Bukowski RM, Tandler C, Cutler D, Rose E, Laughlin MM, Statkevich P. Treating cancer with PEG intron: pharmokinetic profile and dosing guidelines for an improved interferon-α-2b formulation. Cancer95, 389–396 (2002).
   PubMed Web of Science ®Google Scholar
• Gugliotta L, Bulgarelli S, Asioli S et al. Bone marrow evaluation according to the PVSG and WHO criteria in 90 essential thrombocythemia (ET) patients treated with PEG interferon α-2b. Preliminary results. Blood106, 316 (2005) (Abstract 4962).
   Google Scholar
• Silver RT. Recombinant interferon-α for the treatment of polycythemia vera. Lancet2, 403 (1988).
   PubMed Web of Science ®Google Scholar
• Silver RT. A new treatment for polycythemia vera: recombinant interferon α. Blood76, 664–665 (1990).
   PubMed Web of Science ®Google Scholar
• Sacchi S. The role of α-interferon in essential thrombocythemia, polycythemia vera, and myelofibrosis with myeloid metaplasia. Leuk. Lymphoma19, 13–20 (1995).
   PubMed Web of Science ®Google Scholar
• Lengfelder E, Berger U, Hehlmann R. Interferon-α in the treatment of polycythemia vera. Ann. Hematol.79, 103–109 (2000).
   PubMed Web of Science ®Google Scholar
• Foa P, Massaro P, Ribera S et al. Role of interferon α-2a in the treatment of polycythemia vera. Am. J. Hematol.48, 55–57 (1995).
   PubMed Web of Science ®Google Scholar
• Foa P, Massaro P, Caldiera S et al. Long-term therapeutic efficacy and toxicity of recombinant interferon-alpha 2a in polycythaemia vera. Eur. J. Haematol.60, 273–277 (1998).
   PubMed Web of Science ®Google Scholar
• Gilbert HS. Long term treatment of myeloproliferative disease with interferon-α-2b: feasibility and efficacy. Cancer83, 1205–1213 (1998).
   PubMed Web of Science ®Google Scholar
• Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-α. Cancer107, 451–458 (2006).
   PubMed Web of Science ®Google Scholar
• Parmeggianni L, Ferrant A, Rodhain J, Michaux JL, Sokal G. α interferon in the treatment of symptomatic myelofibrosis with myeloid metaplasia. Eur. J. Haematol.39, 228–232 (1987).
   PubMedGoogle Scholar
• Wickramasinghe SN, Stanley P, Gill DS. α-interferon in primary myelofibrosis. Lancet330, 1524–1525 (1987).
   Google Scholar
• Hasselbalch H. Interferon in myelofibrosis. Lancet1, 355 (1988).
   PubMedGoogle Scholar
• Barosi G, Libertato LN, Costa A, Ascari E. Cytoreductive effects of recombinant alpha interferon in patients with myelofibrosis with myeloid metaplasia. Blut58, 271–274 (1989).
   PubMedGoogle Scholar
• Bachleitner-Hofmann T, Gisslinger H. The role of interferon-α in the treatment of idiopathic myelofibrosis. Ann. Hematol.78(12), 533–538 (1999).
   PubMed Web of Science ®Google Scholar
• Radin AI, Kim HT, Grant BW et al. Phase II study of α2 interferon in the treatment of the chronic myeloproliferative disorders. Cancer98, 100–109 (2003).
   PubMed Web of Science ®Google Scholar
• Ludwig H, Linkesch W, Gisslinger H et al. Interferon α corrects thrombocytosis in patients with myeloproliferative disorders. Cancer Immunol. Immunother.25, 266–273 (1987).
   PubMed Web of Science ®Google Scholar
• Muller W, de Wolf JT, Egger R et al. Long-term treatment with interferon-α2b for severe pruritus in patients with polycythemia vera. Br. J. Haematol.89, 313–318 (1995).
   PubMed Web of Science ®Google Scholar
• Ariad S, Bezwoda WR. α-interferon for polycythemia vera. Blood77, 670 (1991).
   PubMed Web of Science ®Google Scholar
• Heis N, Rintelen C, Gisslinger B, Knobl P, Lechner K, Gisslinger H. The effect of interferon α on myeloproliferation and vascular complications in polycythemia vera. Eur. J. Haematol.62, 27–31 (1999).
   PubMedGoogle Scholar
• Cacciola E, Giustolisi R, Guglielmo P, Di Raimondo F, Cacciola E, Calogero RD. Recombinant interferon α in the treatment of polycythemia vera. Blood77, 2790–2796 (1991).
   PubMed Web of Science ®Google Scholar
• Gogas H, Ioannovich J, Dafni U et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med.354, 709–718 (2006).
   PubMed Web of Science ®Google Scholar
• Moschos SJ, Edington HD, Land SR et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon α-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J. Clin. Oncol.24, 3164–3171 (2006).
   PubMed Web of Science ®Google Scholar
• Sacchi S, Kantarjian H, O’Brien S, Cohen PR, Pierce S, Talpaz M. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J. Clin. Oncol.13, 2401–2407 (1995).
   PubMed Web of Science ®Google Scholar
• Steegmann JL, Requena MJ, Martin-Regueira P et al. High incidence of autoimmune alterations in chronic myeloid leukemia patients treated with interferon-α. Am. J. Hematol.72, 170–1706 (2003).
   PubMedGoogle Scholar
• Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C, Fenaux P. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin. Thromb. Hemost.32(4 Part 2), 417–421 (2006).
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J. Clin. Oncol.29, 3907–3913 (2011).
   PubMed Web of Science ®Google Scholar
• Harrison C. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br. J. Haematol.129, 293–306 (2005).
   PubMed Web of Science ®Google Scholar
• Griesshammer M, Struve S, Harrison CM. Essential thrombocythemia/polycythemia vera and pregnancy: the need for an observational study in Europe. Semin. Thromb. Hemost.32(4 Pt 2), 422–429 (2006).
   PubMed Web of Science ®Google Scholar
• Griesshammer M, Struve S, Barbui T. Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy. Blood Rev.22, 235–245 (2008).
   PubMed Web of Science ®Google Scholar
• Robinson S, Bewley S, Hunt BJ, Radia DH, Harrison CN. The management and outcome of 18 pregnancies in women with polycythemia vera. Haematologica90, 1477–1483 (2005).
   PubMed Web of Science ®Google Scholar
• Tulpule S, Bewley S, Robinson SE, Radia D, Nelson-Piercy C, Harrison CN. The management and outcome of four pregnancies in women with idiopathic myelofibrosis Br. J. Haematol.142, 480–482 (2008).
   PubMed Web of Science ®Google Scholar
• Passamonti F, Randi ML, Rumi E et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 617F mutation. Blood110, 485–489 (2007).
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Zankovich R, Diehl V. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis. Haematologica85, 1126–1134 (2000).
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Zankovich R, Diehl V. Clinical and morphological criteria for the diagnosis of prefibrotic idiopathic (primary) myelofibrosis. Ann. Hematol.80, 160–165 (2001).
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM. Prefibrotic chronic idiopathic myelofibrosis – a diagnostic enigma? Acta Hematol.111, 155–1559 (2004).
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM. A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders. Leuk. Lymphoma47, 381–396 (2006).
   PubMed Web of Science ®Google Scholar
• Wilkins BS, Erber WN, Bareford D et al. Bone marrow pathology in essential thrombocythemia: inter-observer reliablity and utility for identifying disease subtypes. Blood111, 60–70 (2008).
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Müllauer L, Buxhofer-Ausch V, Gisslinger B, Gisslinger H. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood117(21), 5710–5718 (2011).
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Antonioli E, Guglielmelli P et al. Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia. Blood110, 840–846 (2007).
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Antonioli E, Guglielmelli P et al. Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden. Leukemia21, 1952–1959 (2007).
   PubMed Web of Science ®Google Scholar
• Larsen TS, Pallisgaard N, Moller MB, Hasselbalch HC. The JAK2 V617F allelle burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis – impact on disease phenotype. Eur. J. Haematol.79, 508–515 (2007).
   PubMed Web of Science ®Google Scholar
• Barosi G, Bergamaschi G, Marchetti M et al.JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood110, 4030–4036 (2007).
   PubMed Web of Science ®Google Scholar
• Kittur J, Knudson RA, Lasho TL et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer109, 2279–2284 (2007).
   PubMed Web of Science ®Google Scholar
• Hsiao HH, Yang MY, Liu YC et al. The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia. Exp. Hematol.35, 1704–1707 (2007).
   PubMed Web of Science ®Google Scholar
• Carobbio A, Finazzi G, Guerini V et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood109, 2310–2313 (2007).
   PubMed Web of Science ®Google Scholar
• Tefferi A, Strand JJ, Lasho TL et al. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia21, 2074–2075 (2007).
   PubMed Web of Science ®Google Scholar
• Steimle C, Lehmann U, Temerinac S et al. Biomarker analysis in polycythemia vera under interferon-α treatment: clonality, EEC, PRV-1, and JAK2 V617F. Ann. Hematol.86(4), 239–244 (2007).
   PubMed Web of Science ®Google Scholar
• Ishii T, Xu M, Zhao Y et al. Recurrence of clonal hematopoiesis after discontinuing pegylated recombinant interferon-α 2a in a patient with polycythemia vera. Hematologica21, 373–374 (2007).
   Google Scholar
• Kiladjian JJ, Massé A, Cassinat B et al. French Intergroup of Myeloproliferative Neoplasms (FIM). Clonal analysis of erythroid progenitors suggests that pegylated interferon α-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. Leukemia24(8), 1519–1523 (2010).
   PubMed Web of Science ®Google Scholar
• Buxhofer-Ausch V, Gisslinger H, Berg T, Gisslinger B, Kralovics R. Acquired resistance to interferon α therapy associated with homozygous MPL-W515L mutation and chromosome 20q deletion in primary myelofibrosis. Eur. J. Haematol.2(2), 161–163 (2009).
   Google Scholar
• Sumi M, Tauchi T, Takaku T, Ohyashiki JH, Ohyashiki K. Successful treatment with interferon-α in a case of acute myeloid leukemia with del (20q) following polycythemia vera. Rinsho. Ketsueki.46(11), 1208–1212 (2005).
   PubMedGoogle Scholar
• Essers MA, Offner S, Blanco-Bose WE et al. IFNα activates dormant haematopoietic stem cells in vivo. Nature458(7240), 904–908 (2009).
   PubMed Web of Science ®Google Scholar
• Sato T, Onai N, Yoshihara H, Arai F, Suda T, Ohteki T. Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion. Nat. Med.15(6), 696–700 (2009).
   PubMed Web of Science ®Google Scholar
• Trumpp A, Essers M, Wilson A. Awakening dormant haematopoietic stem cells. Nat. Rev. Immunol.10(3), 201–209 (2010).
   PubMed Web of Science ®Google Scholar
• Spivak JL, Hasselbalch HC. Hydroxycarbamide: a user’s guide for chronic myeloproliferative disorders. Expert Rev. Anticancer Ther.11(3), 403–414 (2011).
   PubMed Web of Science ®Google Scholar
• Giles FJ, Singer CR, Gray AG et al. Alpha-interferon therapy for essential thrombocythaemia. Lancet2, 70–72 (1988).
   PubMed Web of Science ®Google Scholar
• Bellucci S, Harousseau JL, Brice P, Tobelem G. Treatment of essential thrombocythaemia by alpha 2a interferon. Lancet2, 960–961 (1988).
   PubMed Web of Science ®Google Scholar
• Lazzarino M, Vitale A, Morra E et al. Interferon alpha-2b as treatment for Philadelphia-negative chronic myeloproliferative disorders with excessive thrombocytosis. Br. J. Haematol.72, 173–177 (1989).
   PubMed Web of Science ®Google Scholar
• Giralt M, Rubio D, Cortes MT et al. Alpha interferon in the management of essential thrombocythaemia. Eur. J. Cancer27(Suppl. 4), S72–S74 (1991).
   PubMed Web of Science ®Google Scholar
• Sacchi S, Tabilio A, Leoni P et al. Interferon alpha-2b in the long-term treatment of essential thrombocythemia. Ann. Hematol.63, 206–209 (1991).
   PubMed Web of Science ®Google Scholar
• Turri D, Mitra ME, Di Trapani R, Lipari MG, Perricone R, Cajozzo A. Alpha-interferon in polycythemia vera and essential thrombocythemia. Haematologica76, 75–77 (1991).
   PubMed Web of Science ®Google Scholar
• Seewann HL, Zikulnig R, Gallhofer G, Schmid C. Treatment of thrombocytosis in chronic myeloproliferative disorders with interferon alfa-2b. Eur. J. Cancer27(Suppl. 4), S58–S62; discussion S58–S62 (1991).
   PubMedGoogle Scholar
• Kasparu H, Bernhard M, Krieger O, Lutz D. Remission may continue after termination of rIFN alpha-2b treatment for essential thrombocythemia. Eur. J. Hematol.48, 33–36 (1992).
   PubMed Web of Science ®Google Scholar
• Rametta V, Ferrara F, Marottoli V, Matera C, Mettivier V, Cimino R. Recombinant interferon alpha-2b as treatment of essential thrombocythaemia. Acta Haematol.91, 126–129 (1994).
   PubMed Web of Science ®Google Scholar
• Sacchi S, Gugliotta L, Papineschi F et al. Alfa-interferon in the treatment of essential thrombocythemia: clinical results and evaluation of its biological effects on the hematopoietic neoplastic clone. Italian Cooperative Group on ET. Leukemia12, 289–294 (1998).
   PubMed Web of Science ®Google Scholar
• Saba R, Jabbour E, Giles F et al. Interferon alpha therapy for patients with essential thrombocythemia: final results of a Phase II study initiated in 1986. Cancer103, 2551–2557 (2005).
   PubMedGoogle Scholar
• Cimino R, Rametta V, Matera C, Mele G, Mettivier V, Ferra F. Recombinant interferon alpha-2b in the treatment of polycythemia vera. Am. J. Hematol.44, 155–157 (1993).
   PubMed Web of Science ®Google Scholar
• Finelli C, Gugliotta L, Gamberi B, Vianelli N, Visani G, Tura S. Relief of intractable pruritus in polycythemia vera with recombinant interferon alpha. Am. J. Hemol.43, 316–318 (1993).
   PubMed Web of Science ®Google Scholar
• Papineschi F, Bucallossi A, Capochiani E et al. Recombinant alpha2a interferon and polycythemia vera: clinical results and biological evaluation by means of Fourier-transform infrared microspectroscopy. Eur. J. Haematol.53, 213–217 (1994).
   PubMed Web of Science ®Google Scholar
• Taylor PC, Dolan G, Ng JP, Paul B, Collin R, Reilly JT. Efficacy of recombinant interferon-alpha (rIFN-alpha) in polycythaemia vera: a study of 17 patients and an analysis of published data. Br. J. Haematol.92(1), 55–59 (1996).
   PubMed Web of Science ®Google Scholar
• Tefferi A, Elliot MA, Yoon SY et al. Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. Blood97(6), 1896 (2001).
   PubMed Web of Science ®Google Scholar